NASDAQ · PHVS
Pharvaris N.V.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PHVS: Nov 11, 2026
Pharvaris N.V. Ordinary Shares is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.82. The reported EPS for the same quarter last year was $-0.7.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.82 | $-0.71 | $-0.92 | 5 |
| Dec 2026 | $-0.93 | $-0.84 | $-1.05 | 4 |
| Mar 2027 | $-0.85 | $-0.77 | $-0.99 | 3 |
| Jun 2027 | $-0.81 | $-0.77 | $-0.89 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · BNK Invest · Zacks · Fintel- RTTNews · Oct 9, 1:37 PM EDTWeekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data(RTTNews) – This week, biopharmaceutical companies saw a busy week of regulatory decisions, strategic partnerships and clinical developments, alongside pipeline setbacks and workforce reductions.
- RTTNews · Oct 9, 2:49 AM EDTPharvaris' Deucrictibant XR Cuts HAE Attack Rate By 83%; Plans NDA Filing In H1 2027(RTTNews) – Pharvaris (PHVS), a late-stage biopharmaceutical company, announced that the CHAPTER-3 pivotal Phase 3 study evaluating deucrictibant extended-release (XR) tablets to prevent hereditary angioedema (HAE) attacks met the primary endpoint and all secondary efficacy endpo
- RTTNews · Oct 5, 7:02 AM EDTPharvaris Study Shows HAE Patients Prefer Oral Prophylaxis Over Injections(RTTNews) – Pharvaris N.V. (PHVS) on Monday announced that findings from a company-funded real-world analysis of hereditary angioedema (HAE) management have been published in Advances in Therapy, highlighting persistent gaps between guideline-recommended care and treatment experi
- BNK Invest · Sep 29, 11:56 AM EDTiShares Core MSCI Europe ETF Experiences Big InflowLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI Europe ETF (Symbol: IEUR) where we have detected an approximate $247.7 million dollar inflow — that's a 2.7% increase week over we
- Zacks · Sep 15, 9:50 AM EDTPHVS Stock Rises 10% in a Month: What Is Driving the Rally?Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.
- Fintel · Sep 14, 10:47 PM EDTPharvaris N.V. Consensus Price Target Raised 20.08% to $59.77The average one-year price target for Pharvaris N.V. (NASDAQGS:PHVS) has been revised to $59.77 / share, up 20.08% from the prior estimate of $49.78 dated August 25, 2026. These figures are aggregate analyst targets compiled by Fintel and do not constitute a recommendation by Fi
- RTTNews · Sep 11, 12:06 PM EDTWeekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials(RTTNews) – Biotech and healthcare saw regulatory approvals, strategic partnerships, M&A activity, and a steady stream of clinical trial updates driving investor attention.
- RTTNews · Sep 9, 3:36 AM EDTWedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 Data(RTTNews) – Wedbush Analyst Laura Chico on Tuesday reiterated an Outperform rating and a 12-month price target of $42 for Pharvaris N.V. (PHVS) after the company's pivotal Phase 3 CHAPTER-3 study of deucrictibant XR met its primary endpoint and all secondary efficacy endpoints fo
- RTTNews · Sep 9, 3:06 AM EDTBiotech Stocks At 52-Week Highs – PHVS +7%, ROIV +6% On Trial Readouts, BLSM +4%, ATRC, FTH(RTTNews) – The following biotech stocks reached a 52-week high on September 8, 2026, driven by a series of clinical developments and important regulatory milestones. Pharvaris N.V. (PHVS) Pharvaris is a late-stage biopharmaceutical company developing oral bradykinin B2 recep
- RTTNews · Sep 8, 2:43 PM EDT5 Biotech Stocks To Watch: Bluejay, Pharvaris, Roivant, PDSB & Atara(RTTNews) – Several biotech stocks were in focus Tuesday, including Bluejay Diagnostics following a federal healthcare partnership with Lovell Government Services; Pharvaris after positive Phase 3 CHAPTER-3 results; Roivant following positive Phase 2 PHocus data; PDS Biotech afte
- RTTNews · Sep 8, 7:43 AM EDTPharvaris Reports Positive Phase 3 CHAPTER-3 Results For Deucrictibant XR In HAE Prophylaxis(RTTNews) – Pharvaris N.V. (PHVS) announced positive topline results from the pivotal Phase 3 CHAPTER-3 study evaluating deucrictibant extended-release (XR) tablets for the prevention of hereditary angioedema (HAE) attacks.
- MarketBeat · Sep 6, 8:50 AM EDTModerna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow ItDrug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into the fold, pushing the total to 26 companies covering 89% of the branded drug marke
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Pharvaris N.V. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.